Page last updated: 2024-09-04

docetaxel anhydrous and ly335979

docetaxel anhydrous has been researched along with ly335979 in 2 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (ly335979)	Trials (ly335979)	Recent Studies (post-2010) (ly335979)
12,110	3,216	6,920	112	12	54

Protein Interaction Comparison

Protein	Taxonomy	docetaxel anhydrous (IC50)	ly335979 (IC50)
ATP-dependent translocase ABCB1	Homo sapiens (human)		0.0589

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andre, VA; Arquette, MA; Burgess, MF; de Alwis, DP; Fears, CL; Fracasso, PM; Gazak, RJ; Goldstein, LJ; Goodner, SA; Rader, JS; Schellens, JH; Slapak, CA; Wright, LP	1
Burgess, LJ; Demetriou, GS; Jordaan, JP; Moodley, SD; Nosworthy, AL; Raats, J; Ruff, P; Vorobiof, DA; Werner, ID	1

Trials

2 trial(s) available for docetaxel anhydrous and ly335979

Article	Year
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-01, Volume: 10, Issue:21 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dibenzocycloheptenes; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolines; Taxoids; Time Factors	2004
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dibenzocycloheptenes; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Placebos; Quinolines; Recurrence; Taxoids	2009

Article

Year

Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-01, Volume: 10, Issue:21

Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dibenzocycloheptenes; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolines; Taxoids; Time Factors

2004

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.

Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dibenzocycloheptenes; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Placebos; Quinolines; Recurrence; Taxoids

2009